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RESEARCH ARTICLE
Adherence to HIV antiretroviral therapy among pregnant and
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study in urban South Africa and rural Uganda
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Abstract
Introduction: We conducted a cohort study to understand patterns of anti-retroviral therapy (ART) adherence during preg-
nancy, postpartum and non-pregnancy follow-up among women initiating ART in public clinics offering Option B+ in rural
Uganda and urban South Africa.
Methods: We collected survey data, continuously monitored ART adherence (Wisepill), HIV-RNA and pregnancy tests at zero,
six and twelve months from women initiating ART in Uganda and South Africa, 2015 to 2017. The primary predictor of inter-
est was follow-up time categorized as pregnant (pregnancy diagnosis to pregnancy end), postpartum (pregnancy end to study
exit) or non-pregnancy-related (neither pregnant nor postpartum). Fractional regression models included demographics and
socio-behavioural factors informed by the Behavioral Model for Vulnerable Populations. We evaluated HIV-RNA at 12 months
by ever- versus never-pregnant status.
Results: In Uganda, 247 women contributed 676, 900 and 1274 months of pregnancy, postpartum and non-pregnancy-related
follow-up. Median ART adherence was consistently ≥90%: pregnancy, 94% (interquartile range [IQR] 78,98); postpartum, 90%
(IQR 70,97) and non-pregnancy, 90% (IQR 80,98). Poorer adherence was associated with younger age (0.98% [95% CI 0.33%,
1.62%] average increase per year of age) and higher CD4 cell count (1.01% [0.08%, 1.94%] average decrease per 50 cells/
mm3). HIV-RNA was suppressed among 91% (N = 135) ever-pregnant and 86% (N = 85) never-pregnant women. In South
Africa, 190 women contributed 259, 624 and 1247 months of pregnancy, postpartum and non-pregnancy-related follow-up.
Median adherence was low during pregnancy, 74% (IQR 31,96); postpartum, 40% (IQR 4,65) and non-pregnancy, 77% (IQR
47,92). Poorer adherence was associated with postpartum status (22.3% [95%CI 8.6%, 35.4%] average decrease compared to
non-pregnancy-related follow-up) and less emotional support (1.4% [0.22%, 2.58%] average increase per unit increase). HIV-
RNA was suppressed among 57% (N = 47) ever-pregnant and 86% (N = 93) never-pregnant women.
Conclusions: Women in rural Uganda maintained high adherence with 91% of ever-pregnant and 86% of never-pregnant
women suppressing HIV-RNA at 12 months. Women in urban South Africa struggled with adherence, particularly during post-
partum follow-up with median adherence of 40% and 57% of women with HIV-RNA suppression at one year, suggesting a cri-
sis for postpartum women with HIV in South Africa. Findings suggest that effective interventions should promote emotional
support.
Keywords: adherence; ARV; Cohort studies; gender; Africa < Region; women; HIV; adherence; ARV; cohort studies; gender;
Africa < Region; women; HIV
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1 | INTRODUCTION
In 2013, the WHO updated guidelines for prevention of
mother to child transmission of HIV (PMTCT) to recommend
antiretroviral treatment (ART) for pregnant or breastfeeding
women living with HIV (WLWH), either during pregnancy and
breast-feeding periods only (“Option B”), or for life (“Option
B+”), regardless of CD4 count. The goal was to simplify ser-
vice delivery while reducing perinatal transmission in current
and subsequent pregnancies, drug resistance from episodic
antiretroviral exposure, maternal morbidity and mortality, and
sexual transmission [1].
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Data from earlier PMTCT eras when women were offered
prophylactic antiretrovirals to reduce perinatal transmission
risks highlight adherence challenges during pregnant and post-
partum periods [2-6]. Data suggested that taking ART to sup-
port their child and their own health may promote improved
adherence for women [7]. More recent data after institution
of Option B+, however, show low rates of viral suppression
and high losses to follow-up: for example in eSwatini 53%
postpartum retention in care [8], in Tanzania 39% viral sup-
pression at 12 months postpartum [9]. Follow-up studies with
tracing of women lost to specific clinic follow-up show that
some women are in care elsewhere, though overall postpar-
tum retention in care estimates remain sub-optimal [10]. For
women retained in care, adherence to therapy remains a chal-
lenge. In Mpumalanga Province, South Africa, self-reported
adherence to ART was 69% among pregnant WLWH [11] and
in Zimbabwe, only 40% of women were taking at least 95% of
ART by pill count one year postpartum [12]. Qualitative data
from sub-Saharan African sites suggest that adherence chal-
lenges for pregnant and postpartum WLWH relate to struc-
tural barriers to care, community and healthcare stigma,
medication side effects, depression, substance use and the
overwhelming challenges of poverty, gender norms, and life
with a newborn [13-20].
To better understand adherence patterns relative to preg-
nancy among women initiating ART in rural, southwestern
Uganda and urban South Africa in the Option B+ era, we eval-
uated daily ART adherence over the first year of treatment in
a cohort with low losses to follow-up. We evaluated the
impact of pregnancy and postpartum follow-up and associated
factors on daily objectively measured adherence and viral sup-
pression in two diverse African settings. Findings may inform
interventions to maximize health and reproductive choice for
women, infants and families.
2 | METHODS
2.1 | Study settings
In Uganda, participants were recruited from five health cen-
tres in a rural region of southwestern Uganda. Clinics included
a tertiary care referral site, as well as outpatient clinics pro-
viding HIV testing and care. All are located approximately
275 km from Kampala in a largely rural area where HIV
prevalence is estimated at 8% for adults and 11% among
women accessing antenatal care [21]. Option B+ for PMTCT
was implemented in 2013 [22]. Postpartum WLWH are seen
together with their infants at four, six, ten and sixteen weeks,
and then monthly until 18 months postpartum when women
are referred to general HIV care and infants are discharged
from the PMTCT clinic.
In South Africa, participants were recruited from three HIV
clinics providing integrated HIV care in Gugulethu – an urban
township near Cape Town where provincial HIV prevalence is
estimated at 13% for adults and 19% for women attending
antenatal care [23,24]. Option B+ for PMTCT was rolled out
widely in 2015 [25] and deployed at these sites in 2013 [26].
Per local standard of care, all women were transferred to gen-
eral ART services after delivery – either after the first routine
postpartum visit or when they return for the next ART
appointment after delivery.
2.2 | Participants
Individuals were recruited between March 2015 and Septem-
ber 2016. Inclusion criteria included being ART-na€ıve and initi-
ating ART within one month of enrolment date, ≥18 years of
age, living within 60 km of the recruitment clinic, and intend-
ing to stay in the area for the next year. Enrolled pregnant
participants who were at least 34 weeks pregnant per best-
available estimates were excluded (to maximize pregnancy fol-
low-up time). Inability to provide informed consent was an
exclusion criterion.
The parent study enrolled women with CD4 counts
<200 cells/mm3 and CD4 counts >350 cells/mm3 for the pri-
mary study question assessing whether initial CD4 cell count
(and associated immune function) influences adherence. Preg-
nant women were only included in the parent study if their
CD4 count was at least 350 cells/mm3 at enrolment. There-
fore, this analysis is limited to women who enrolled with CD4
count at least 350 cells/mm3 to reduce selection bias. Results
for all participants are published elsewhere [27].
2.3 | Study procedures
Participants received routine care at their local clinics. Stan-
dard first-line ART (generic tenofovir/emtricitabine/efavirenz
in a combination pill) was provided by the study to avoid
adherence variations due to formulation or stock outs;
changes in ART were made per routine clinical guidance. Par-
ticipants completed study visits at enrolment, six and twelve
months and provided blood for HIV-1 RNA (determined by
the Cobas Taqman Test in Uganda and the Roche CAP/CTM
HIV-1 v2 assay in South Africa) and completed survey ques-
tionnaires. Women <50 years of age provided urine for beta-
hCG analysis at each study visit.
Socio-behavioural factors potentially-relevant for adherence
were chosen based on the Behavioral Model for Vulnerable
Populations [28] and included socio-demographics, structural
barriers to care (13-item scale, scored 0 to 52, higher scores
indicate more barriers [29]), food insecurity (9-item House-
hold Food Insecurity Access Scale [30], scored 0 to 27), HIV
stigma (12 items adapted from the Berger HIV Stigma Scale
[31] exploring perceived negative attitudes and disclosure con-
cerns, total scoring range 1 to 4, higher score indicating more
stigma), HIV disclosure, coping (7 item scale, scoring range 1
to 4, higher score indicating more maladaptive coping [32]),
medical mistrust/conspiracy (8 item scale, scoring range 1 to
4, higher score indicating more mistrust/conspiracy [33]),
necessity and concerns about taking ART (19 item scale [34]),
clinic satisfaction (19 item scale, scoring range 1 to 4, higher
score indicating more satisfaction [35]), mental and physical
health (MOS-HIV, 35 items, scored 0 to 100, normalized with
50 indicating average health in a US population [36]), Hopkins
Symptom Checklist (HSCL) to screen for anxiety and depres-
sion (25 items, each rated 1 to 4, average score of ≥1.75
indicative of high-risk for psychological distress [37-39], Edin-
burg Postnatal Depression Score (EPDS) (10 item score, range
0 to 30 with score of ≥13 indicating positive screen for
depression) [37,40] and high-risk alcohol use (AUDIT-C
[41,42]). The degree of emotional or instrumental support (de-
scribed to participants in general terms for their own inter-
pretation) received from social network ties was assessed by
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using name generator questionnaires to elicit up to 20 ties,
each of whom were rated for the degree of support provided
to the participant [43]. The social support score reflects the
proportion of each participant’s supporters who were catego-
rized as completely supportive. Adherence was monitored
with a real-time electronic adherence monitor that transmits a
date-and-time stamp via cellular networks for all opening
events as a proxy for medication ingestion (Wisepill Technolo-
gies, Cape Town, South Africa).
2.4 | Analysis
2.4.1 | Descriptive statistics
Participant characteristics were summarized descriptively by
study site and ever-pregnant status. Comparisons between
sites were made with Wilcoxon rank sum and Fisher’s exact
test for continuous and categorical variables respectively.
Primary predictor
The primary predictor of interest was women’s pregnancy sta-
tus over 12-month follow-up. Follow-up time for each woman
was categorized as pregnant, postpartum or non-pregnancy-
related. Women with positive beta-hCG were categorized as
pregnant. Women reporting a birth outcome with a date were
categorized as postpartum from that date, including for pre-
term pregnancy losses. Women who were no longer pregnant
by beta-hCG testing and did not have a birth outcome
reported were counted as postpartum from 40 weeks after
their last menstrual period or to include a total pregnancy
length of approximately 40 weeks. Once classified as postpar-
tum, women remained postpartum through the rest of the
study (no repeat pregnancies were observed). Median post-
partum follow-up time was 7.4 months (interquartile range
[IQR], 5.5 to 8.8) in Uganda and 9.2 months (IQR, 7.6 to 11.3)
in South Africa. Women without pregnancy detected or
reported during follow-up contributed to non-pregnancy-
related time.
To test our hypothesis that adherence may differ by preg-
nant, postpartum and non-pregnancy-related status, we fitted
fractional regression models with cluster-correlated robust
estimates of variance to the pooled data [44]. ART adherence
was specified as a proportion ranging from 0 to 1 inclusively.
For the conditional mean model, we specified a logistic model
and made no assumptions about the distribution of the mod-
el’s unobserved components. Covariate selection was guided
by the Theory of Vulnerable Populations [28]. In the event
that the theoretical model suggested multiple potentially colli-
near variables (e.g. food insecurity and socio-economic status),
we selected covariates that were most relevant based on the
enrolment data. Data from women in Uganda and South Africa
were analysed separately because of baseline socio-economic
and cultural differences which could affect adherence
(Table 1). To facilitate interpretation, the estimated regression
coefficients were converted to average marginal effects, or a
change in adherence corresponding to a unit change in the
explanatory variable of interest, with the values of all other
explanatory variables as is. For continuous variables (e.g. age)
the average marginal effect corresponds to the first derivative
of the response with respect to the variable in question. For
discrete variables (e.g. pregnancy status), the average marginal
effect corresponds to a discrete change effect and is inter-
preted relative to the reference group; in effect, this calcula-
tion compares two hypothetical populations that have same
values for the other explanatory variables in the model.
2.4.2 | Outcomes
Adherence
Adherence was calculated as the number of electronic adher-
ence monitor opening events observed divided by the number
of opening events expected during follow-up. Adherence was
capped at 100% per day and censored at death. Adherence
for participants lost to follow-up (LTFU), defined as no contact
despite multiple attempts through 13 months after enrolment,
was calculated until the device stopped transmitting data or
until the last scheduled study visit – whichever came first.
Monitor opening events related to staff openings and during
periods of known device malfunction were removed from the
data [45].
Adherence interruptions of seven or more days were also
assessed [46]. Adherence distributions between groups of
never- and ever-pregnant women were compared by the Wil-
coxon rank sum test.
To compare adherence before and after the expected due
date, first we visually inspected the distribution of adherence
over time. To formally assess the difference in median adher-
ence before vs. after the expected due date, we included an
interaction term in the regression models.
In sensitivity analyses, we imputed adherence data for
women LTFU as either [1] mean adherence prior to loss to
follow-up or [2] mean adherence for postpartum women with
adherence data. These means were compared with the pri-
mary (non-imputed) results via Student’s t-test.
HIV-RNA suppression
Viral suppression was defined as <400 copies/mL. Participants
were defined to be viraemic if they died (any cause). Those
LTFU or who had missed visits and had <80% adherence in
the month prior to the missed visit were counted as viraemic.
All analyses were conducted in Stata 13 (StataCorp., Col-
lege Station, TX, USA).
2.4.3 | Ethics
This study was approved by the human research ethics com-
mittees of Partners Healthcare, Mbarara University of Science
and Technology, and the University of Cape Town. Additional
regulatory approvals were secured from the Uganda National
Council for Science and Technology and the Western Cape
province in South Africa.
3 | RESULTS
3.1 | Demographics
This analysis includes 247 women in Uganda and 190 women
in South Africa. In Uganda, 129 (39%) women were pregnant
at enrolment and an additional 19 (6%) women had pregnan-
cies over the course of follow-up. Participants in Uganda
contributed 676 months of pregnancy follow-up time,
900 months of postpartum follow-up time and 1274 months
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Table 1. Key enrolment demographics and socio-behavioural factors informed by the Behavioral Model for Vulnerable Populations
by site and never/ever pregnant status
Characteristic
Uganda
Mean (SD) or N (%)
South Africa
Mean (SD) or N (%)
p value for all
Ugandan vs.
all SA women
All
(N = 247)
Never pregnant
(N = 99)
Ever pregnant
(N = 148)
All
(N = 190)
Never pregnant
(N = 108)
Ever pregnant
(N = 82)
Demographics
Age 29 (9) 32 (11) 26 (5) 31 (9) 35 (10) 27 (5) 0.001*
Pregnant at
enrolment
129 (52) – 76 (40) – 0.012*
Incident pregnancy
during follow-up
19 (16) – 6 (5) – 0.01*
Married 143 (59) 34 (34) 109 (76) 29 (15) 22 (20) 7 (9) <0.001*
Highest education <0.001*
None/primary 84 (35) 42 (42) 42 (29) 14 (7) 9 (8) 5 (6)
Secondary 159 (65) 57 (58) 102 (71) 175 (93) 99 (92) 76 (94)
Employed 187 (77) 86 (87) 101 (70) 75 (40) 49 (45) 26 (32) <0.001*
Structural barrier score 29 (12) 3.5 (5.6) 2.7 (5.6) 82 (43) 13.3 (7.1) 15.0 (7.2) <0.001*
Health
Median CD4
count (cells/mL)
477 (421, 618) 441 (399, 485) 554 (438, 676) 440 (394, 490) 426 (386, 462) 477 (413, 662) <0.001*
Median HIV-RNA
(log10 c/mL)
3.6 (2.5, 4.3) 3.6 (2.6, 4.4) 3.6 (2.2, 4.3) 4.2 (3.6, 4.6) 4.2 (3.6, 4.8) 4.2 (3.4, 4.5) <0.001*
HIV dx greater
than 30 days
prior to
enrolment
221 (91) 96 (97) 125 (87) 138 (79) 96 (99) 42 (55) <0.001*
Median days from
diagnosis to
enrolment
59 (4, 874) 285 (8, 1808) 34 (2.5, 420.5) 40.5 (2, 730) 73 (22, 797) 1 (0, 383) 0.286
Mental wellbeing 48 (11) 47 (11) 48 (11) 38 (9) 39 (9) 38 (8) 0.001*
Physical wellbeing 41 (5) 41 (4) 41 (5) 44 (8) 44 (8) 45 (7) <0.001*
Depressed
(>9 on EPDS)
55 (23) 24 (24) 31 (22) 105 (56) 65 (60) 40 (49) <0.001*
Coping score 2.2 (0.4) 2.2 (0.4) 2.4 (0.3) 2.3 (0.2)
Severe food
insecurity
69 (28) 32 (32) 37 (26) 121 (64) 68 (63) 53 (65) <0.001*
Heavy alcohol use 19 (8) 10 (10) 9 (6) 47 (25) 30 (28) 17 (21) <0.001*
Medications other
than ART
207 (85) 90 (91) 117 (81) 25 (13) 22 (20) 3 (4) <0.001*
Cigarette use 5 (2) 3 (3) 2 (1) 27 (14) 16 (15) 11 (14) <0.001*
Reproductive health history
# of biological children 2 (0, 3) 2 (1, 4) 1 (0, 2) 1 (1, 2) 2 (1, 3) 1 (1, 2) 0.27
Estimated GA at
enrolment, weeks
(limited to those
enrolling pregnant)
– – 19 (12, 24) – – 24 (19, 28) <0.001*
Partner/relationships
Relationship w/main partner
Spouse 149 (69) 37 (49) 112 (81) 45 (27) 30 (33) 15 (19) <0.001*
Regular 55 (26) 33 (43) 22 (16) 118 (69) 55 (61) 63 (79)
Other 11 (5) 6 (8) 5 (4) 7 (4) 5 (6) 2 (2)
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of non-pregnancy-related follow-up time. At enrolment, Ugan-
dan women had a mean age of 29 years (standard deviation
(SD), 9); 59% were married. Most (77%) reported formal or
informal employment with 28% reporting severe food insecu-
rity but a low structural barrier score (median 0). Median
CD4 cell count was 477 cells/mm3 (IQR, 421 to 618) and
most (91%) reported being diagnosed with HIV at least one
month prior to enrolment. Thirty-six percent reported a main
partner living with HIV; 51% did not know their partner’s
serostatus. Fifty-five (23%) met screening criteria for
Table 1. (Continued)
Characteristic
Uganda
Mean (SD) or N (%)
South Africa
Mean (SD) or N (%)
p value for all
Ugandan vs.
all SA women
All
(N = 247)
Never pregnant
(N = 99)
Ever pregnant
(N = 148)
All
(N = 190)
Never pregnant
(N = 108)
Ever pregnant
(N = 82)
Main partner HIV
serostatus
0.055
Negative 27 (13) 8 (11) 19 (14) 22 (13) 14 (15) 8 (10)
Positive 78 (36) 30 (39) 48 (34) 44 (25) 31 (33) 13 (16)
Don’t know 110 (51) 38 (50) 72 (52) 108 (57) 49 (52) 58 (73)
Refused –- –- 0 (0) 1 (1)
Physical violence
past six months
31 (18) 12 (19) 19 (17) 6 (3) 3 (3) 3 (4) <0.001*
Exchange money
for sex past
six months
33 (14) 11 (11) 22 (15) 3 (2) 1 (1) 2 (3) <0.001*
Forced sex past
six months
33 (14) 11 (12) 22 (15) 9 (5) 7 (7) 2 (3) 0.002*
Disclosure/stigma/social support/relationship with HC system
Disclosed aside
from healthcare
worker
188 (77) 79 (80) 109 (76) 137 (73) 92 (85) 45 (56) 0.24
Disclosed outside
of household
123 (51) 60 (61) 63 (44) 74 (39) 55 (51) 19 (24) 0.025*
Stigma: perceived
negative attitudes
towards HIV
1 (0, 4) 1 (0, 3) 2 (0, 4) 3 (0, 4) 3 (1, 4) 2 (0, 4) 0.032*
Stigma: disclosure
concerns
5 (2, 6) 4 (1, 6) 5 (2, 7) 3 (1, 6) 3 (1, 5.5) 4 (1, 6) 0.06
Instrumental
support
0.4 (0.2) 0.4 (0.2) 0.4 (0.2) 0.5 (0.3) 0.5 (0.3) 0.6 (0.3) <0.001*
Emotional support 0.5 (0.3) 0.5 (0.3) 0.6 (0.3) 0.8 (0.3) 0.7 (0.3) 0.6 (0.3) <0.001*
Healthcare system/medication trust
Medical mistrust 1.75 (1, 2.5) 1.75 (1, 2.25) 1.75 (1, 2.5) 3 (2, 2.5) 2 (2, 2.5) 2 (2, 2.5) <0.001*
Conspiracy 1.9 (0.7) 1.9 (0.7) 1.9 (0.7) 2.3 (2, 2.5) 2.3 (2, 2.7) 2.3 (2, 2.5) <0.001*
Clinic satisfaction 3.5 (0.4) 3.5 (0.4) 3.5 (0.4) 3.1 (0.4) 3.1 (0.4) 3.1 (0.4) <0.001*
ART need
Low 40 (16) 17 (17) 23 (16) 87 (46) 46 (43) 41 (51) <0.001*
Moderate 94 (39) 40 (40) 54 (38) 81 (43) 50 (46) 31 (38)
High 109 (45) 42 (42) 67 (47) 21 (11) 12 (11) 9 (11)
ART concerns
Low 46 (19) 11 (11) 35 (24) 8 (4) 4 (4) 4 (5) <0.001*
Moderate 74 (31) 41 (41) 33 (23) 67 (36) 37 (34) 30 (37)
High 123 (51) 47 (48) 76 (53) 114 (60) 67 (62) 47 (58)
All p-values determined by Fishers exact test for categorical and Wilxocon rank sum for continuous variables between all Uganda women and all
South Africa women. Values in italics are dichotomous variables listed as N (%). Remaining variables are continuous and either listed as mean (SD)
or median (IQR).
*Significant at p < 0.05 level.
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depression by HSCL, 30 (30%) met screening criteria by
EPDS and 19 (8%) reported heavy alcohol use. (Table 1).
In South Africa, 76 (26%) women were pregnant at enrol-
ment and an additional 6 (2%) women had pregnancies during
follow-up. Participants contributed 259 months of pregnancy
follow-up time, 624 months of postpartum follow-up time and
1247 months of non-pregnancy-related-follow-up time. At
enrolment, participants had a median age of 31 years (SD, 9);
15% were married. Few (40%) reported formal or informal
employment with 64% reporting severe food insecurity and a
high structural barrier score (median 13; IQR, 8 to 18). Med-
ian CD4 cell count was 440 cells/mm3 (IQR, 394 to 490) and
79% reported being diagnosed with HIV at least one month
prior to enrolment. Most (61%) did not know their partner’s
serostatus. Over half (56%) met the screening criteria for
depression by HSCL, 30 (40%) met screening criteria by
EPDS and 47 (25%) reported heavy alcohol use. Ever-preg-
nant women in South Africa were younger and more likely to
have been diagnosed with HIV in the last 30 days. (Table 1).
A total of 39/437 (9%) women across both sites (15/247,
6% in Uganda and 24/190, 13% in South Africa) had incom-
plete data including those who were LTFU (7 in Uganda and
13 in SA), disenrolled (4 in Uganda and 11 in SA) or died (4 in
Uganda). Among these 39 women, 16 women (4 in Uganda
and 12 in SA) contributed no adherence data; 23 women (11
in Uganda and 12 in SA) maintained Wisepill devices con-
tributing adherence data for a mean of 78 (SD, 97) days. For
14 women (4 in Uganda, 10 in South Africa) viral load data
were missing.
3.2 | Adherence
3.2.1 | Uganda
In Uganda, median adherence to ART for women during preg-
nancy, postpartum and non-pregnancy-related periods was
94% (IQR, 78% to 98%), 90% (IQR, 70% to 97%), 90% (IQR,
80% to 98%) (p = 0.017). Figure 1 plots adherence relative to
pregnancy period follow-up and estimated due date, demon-
strating a downward trend in median adherence after due
date (p < 0.001). Seven-day interruptions were rare for all
women (median, 0; IQR, 0 to 1). Imputing adherence for those
women LTFU as either the mean for their adherence prior to
loss to follow-up group or the mean for postpartum women
LTFU but with adherence data, did not result in statistically
different adherence estimates. Mean adherence was indepen-
dently associated with age (average 0.98% increase in adher-
ence per year of age; 95% CI, 0.33% to 1.62%) and CD4 cell
count (average 1.01% decrease per 50 cells/mm3 increase in
CD4 count; 95% CI, 0.08% to 1.94%) (Table 2).
In Uganda, 135 (91%) and 85 (86%) of ever- and never-
pregnant women achieved HIV-RNA suppression at
12 months of follow-up. If we assume that all women LTFU or
otherwise missing were in care and suppressed, then 138/148
(93%) ever pregnant women and 89/99 (89%) never-pregnant
women were virally suppressed at one-year follow-up (Fig-
ure 2).
3.2.2 | South Africa
Among South African participants, median ART adherence was
74% during pregnant periods (IQR, 31% to 96%), 40% during
postpartum (IQR, 4% to 65%) and 77% during non-pregnancy
periods (IQR, 47% to 92%) (p < 0.001). Daily median adher-
ence relative to pregnancy period follow-up and estimated
due date demonstrates a downward trend after due date
(p < 0.001) (Figure 1). The median (IQR) number of seven-day
interruptions was 0 during pregnant periods (IQR, 0 to 0.6),
0.4 during postpartum (IQR, 0.1 to 0.7) and 0.2 during non-
pregnancy periods (IQR, 0 to 0.4). Imputing adherence for
women LTFU as either the mean for their adherence prior to
loss to follow-up or the mean for postpartum women LTFU
Figure 1. Average (IQR) adherence relative to due date among pregnant women living with HIV and accessing ART in Uganda and South
Africa (Only women with pregnancy included in this analysis).Change in slope for median and 25th percentile statistically significant
(p < 0.001) for Uganda cohort. All slopes statistically significant (p < 0.001) for the South Africa cohort.
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but with adherence data did not result in statistically different
adherence estimates. Mean adherence was associated with
postpartum follow-up (average 22.3% lower adherence during
postpartum compared with non-pregnancy-related follow-up;
95% CI, 8.6% to 35.4%) and emotional support (average 1.4%
higher adherence per unit of increased emotional support;
95% CI, 0.22% to 2.58%).
HIV-RNA suppression was achieved by 47 (57%) and 93
(86%) of ever- and never-pregnant women (Figure 2). If we
assume that those LTFU or missing HIV-RNA data were in
care elsewhere, then up to 57 (69%) ever-pregnant women
and 99 (92%) never-pregnant women were virally suppressed
(Figure 2).
4 | DISCUSSION
In this observational study capturing daily adherence beha-
viour among women enrolled with CD4 counts of ≥350 cells/
mm3, postpartum status was independently associated with
worse adherence compared to non-pregnant status in South
Africa. Postpartum women in South Africa adhered to a med-
ian of 40% of daily ART doses and only 57% of women with a
pregnancy achieved HIV-RNA suppression one year after
starting ART. In adjusted models, emotional support indepen-
dently affected adherence. We also observed preservation of
adherence and 91% one-year viral suppression among women
with pregnancy in rural Uganda. Importantly, there were low
losses to follow-up and medications were provided by the
study, highlighting challenges with daily pill taking even when
women remain in care. These data indicate the importance of
local context and an urgent situation in South Africa with poor
adherence leading to viremia in pregnant and postpartum
women.
Policy makers, clinicians and advocates hoped that simpler
regimens and messages emphasizing the importance of ART
to women’s health would improve adherence and HIV out-
comes for women. Our findings indicate ongoing challenges,
particularly in the South African cohort, during the postpartum
period. Daily adherence data support earlier observations: the
postpartum period is fraught with challenges and serves as a
“cliff” in HIV care adherence [16]. In the current era where
most women living with HIV access ART, at least half of new
infections occur during breastfeeding – including in South
Africa and Uganda where nearly all pregnant WLWH access
ART [47]. While adherence counselling through pregnancy
tends to focus on the health of the child, and women may
focus on the goal of delivering an HIV-uninfected child, post-
partum messaging may be less clear, particularly when women
do not receive postpartum-specific HIV care. Yet viremia post-
partum has dire consequences for breastfeeding infants.
Qualitative data published from this cohort described preg-
nancy and the postpartum state as “de-stabilizing experiences”
in which multiple factors including changes in the relationship
with the father of the child (leading to poverty and lack of
emotional support), inability to work and provide for oneself
and physical symptoms compromise adherence [48]. Many
women are diagnosed with HIV in pregnancy (nearly half of
pregnant women in the South Africa cohort were diagnosed in
the month prior to study enrolment); the concomitant stigma
of living with HIV and having a pregnancy may further compli-
cate medication adherence [49-54]. Postpartum, acute worries
around delivering a healthy infant may resolve after birth and
change motivations for remaining on treatment or in care
[14,15]. The stress of caring for a newborn can be overwhelm-
ing, leaving little time for self-care. In South Africa, women are
generally transferred from obstetric care to another clinic
upon delivery, resulting in potential for losses to follow-up,
confusion, logistical challenges, and/or suboptimal support [17]
[26].
Nine percent of women were LTFU, disenrolled or died. We
were unable to trace all women and therefore some of those
LTFU may have been retained in care. However, even if all
women LTFU had remained in care and achieved HIV-RNA
suppression, we would still observe low rates of viral suppres-
sion among women in South Africa. Retention in HIV care
Table 2. Correlates of ART adherence as measured with daily
monitoring of pill cap openings among women in Uganda (a)
and South Africa (b)
Covariate
Average
marginal
effect 95% CI
a. Uganda
Non-pregnancy-related follow-up Ref Ref
Pregnancy follow-up 0.0617 0.0079, 0.1313
Postpartum follow-up 0.0074 0.0704, 0.0853
Age 0.0098 0.0033, 0.0162
CD4 cell count (per 50 cells) 0.0101 0.0194, 0.0008
Highest education – secondary 0.0104 0.0489, 0.0696
Structural barrier score 0.0020 0.0082, 0.0042
Perceived stigma 0.0145 0.0313, 0.0023
Severe food insecurity 0.0425 0.1128, 0.0277
Depressed (EPDS > 9) 0.0254 0.0614, 0.1122
Alcohol abuse (AUDIT-C) 0.0499 0.1539, 0.0540
Instrumental support 0.0033 0.0018, 0.0085
Emotional support 0.0013 0.0059, 0.0033
Main sexual partner relationship 0.0038 0.1000, 0.0925
b. South Africa
Non-pregnancy-related follow-up Ref. Ref.
Pregnancy follow-up 0.0512 0.0766, 0.1791
Postpartum follow-up 0.2229 0.3540, 0.0859
Age 0.0028 0.0054, 0.0110
CD4 count (per 50 cells) 0.0113 0.0094, 0.0340
Highest education – secondary 0.0276 0.2180, 0.1628
Structural barrier score 0.0039 0.0044, 0.0121
Perceived stigma 0.0154 0.0177, 0.0484
Severe food insecurity 0.0389 0.1648, 0.0869
Depressed (EPDS > 9) 0.0022 0.1195, 0.1150
Alcohol abuse (AUDIT-C) 0.0743 0.2139, 0.0653
Instrumental support 0.0093 0.0215, 0.0029
Emotional support 0.0140 0.0022, 0.0258
Main sexual partner relationship 0.0126 0.1360, 1612
Boldface type indicates statistical significance at the p < 0.05 level.
The joint p-value for the adjusted association between pregnancy sta-
tus and adherence is 0.0102 for the Ugandan sample and <0.0001 for
the South African sample. Estimated regression coefficients have been
converted to average marginal effects for ease of exposition.
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remains an important issue for pregnant and postpartum
women living with HIV [55,56]. In the Ugandan sites, where
adherence was high and losses to follow-up minimal, women
live in rural settings where most farm and are relatively non-
mobile. In addition, WLWH remain in mother-baby coupled
clinical care until 18 months postpartum.
In South Africa, the only factor independently associated
with adherence in addition to postpartum follow-up was emo-
tional support which may be crucial to helping women over-
come structural barriers to access care or physical challenges
associated with being postpartum [48]. Details on the types of
emotional support provided were not assessed in survey data,
but in qualitative data, participants described the importance
of reminders and encouragement to take their medication
from social supports [48]. Among women in Uganda, older age
and lower baseline CD4 cell count were associated with
improved adherence. Older age is a factor frequently associ-
ated with greater ART adherence perhaps related to health
literacy and life stability [57,58], although this observation lar-
gely focuses on those ages >50 years; the age range of this
study was limited to those age ≤50. Studies of women taking
HIV pre-exposure prophylaxis (PrEP) observe improved adher-
ence with increasing age in younger cohorts [59], perhaps
related to neurodevelopmental factors [60]. A combination of
both factors may be relevant in this cohort of relatively young
women. Some have postulated that a lower baseline CD4 cell
count and poorer health could prompt increased motivations
to adhere to therapy [61,62], which may be relevant here. That
said, all of the women in this analysis initiated therapy with a
relatively preserved CD4 cell count (i.e. ≥350 cells/mm3).
Some interventions to support women to transition from
PMTCT to general ART care and to retain postpartum women
in ART programmes will promote emotional support in ongo-
ing studies with peer navigators/mentor mothers [63,64] as
well as increased male involvement [65]. In addition, studies
addressing structural factors showed promising results with
integration of postpartum care into routine care for the child
or family [66] [67], mHealth reminders and cash transfers
[68-72]. Ongoing studies will evaluate effects of mHealth
strategies [73,74], reaching women with mental health chal-
lenges in pregnancy and postpartum [75,76] and adherence
clubs/decentralized care [77]. Women in different contexts will
require different types of support [78,79] and an adaptive
trial design [80] may be an efficient way to evaluate strategies
to combine intervention elements to support women to
remain in care [81].
This observational study has limitations. We did not follow-
up infants for perinatal transmission outcomes. Additionally,
there is potential for device non-use to influence adherence
data resulting in misclassification bias. Notably, previous stud-
ies have found to be moderate correlation between electronic
monitoring and drug concentration in blood [82,83], and the
HIV-RNA data in this study align with the adherence findings.
Strengths include inclusion of women from urban South Africa
and rural Uganda with longitudinal objective adherence mea-
surement, HIV-RNA, minimal losses to follow-up and models
including behavioural factors that influence adherence based
on a conceptual framework.
5 | CONCLUSIONS
Many WLWH struggle to remain in care and on ART during
the postpartum period. For their own health and that of their
infants, effective, context-specific interventions are needed to
support women in this critical period. These data suggest that
interventions to provide emotional support during the post-
partum period for younger women may be important.
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